Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.

Selvaggi, G.Wu, Y.Wang, Z.Wu, G.Poddubskaya, E.Reck, M.Mok, T.2024-06-122024-06-1220211556-08641556-1380https://hdl.handle.net/20.500.14551/18274[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessALKNSCLCEnsartinibQuality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.Conference Object163S232S233Q1WOS:000631349600306